Regencell Bioscience (RGC)
Develops standardized traditional Chinese medicine formulas for ADHD and autism spectrum disorder.
$6.30
Pre-market+0.03 (+0.48%)
At close$6.27(+14.00%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions37 holders · as of Mar 31, 2026 | 0.13% | 647.2K ADS | |
| Insiders3 holders · as of Mar 18, 2026 | 88.62% | 439.08M ADS | |
| Otherremainder | 11.25% | 55.75M ADS |
495.47M ADS as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count is from the company's Jun 2025 annual report; nothing newer is on file here.
Institutions13F, as of Mar 31, 2026
37 holders · 647.2K shares · 18 new positions · 25 increased · 6 reduced · 4 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Geode Capital Management, LLC | 415.6K | 0.08% | +2.5K | May 15, 2026 |
| Marex Group PLC | 31.6K | 0.01% | +31.6Knew | May 13, 2026 |
| Gsa Capital Partners LLP | 31.6K | 0.01% | +31.6Knew | May 8, 2026 |
| Vident Advisory, LLC | 29.6K | 0.01% | −346 | May 15, 2026 |
| Squarepoint Ops LLC | 26.6K | 0.01% | +602 | May 15, 2026 |
| UBS Group AG | 23.9K | 0.00% | +5.7K | May 5, 2026 |
| Morgan Stanley | 20.1K | 0.00% | −1.3K | May 15, 2026 |
| Bank of America Corp /DE/ | 17.2K | 0.00% | +17.1K | May 18, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Yat-Gai Auincl. Regencell (BVI) Limited | 88.60% | 437.90M | 13D | Jul 11, 2025 ↗ |
Insider tradesForm 4
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.